Chapel Hill, NC, United States of America

Hai Yan

USPTO Granted Patents = 36 (Patent Applications = 13)

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 16 (Patent Applications = 15)

Average Co-Inventor Count = 3.5

ph-index = 9

Forward Citations = 204(Granted Patents)

Location History:

Baltimore, MD (US) (2002)
Newbury Park, CA (US) (2011 - 2012)
Durham, MD (US) (2020)
Chapel Hill, NC (US) (2006 - 2022)
Thousand Oaks, CA (US) (2006 - 2022)
Durham, NC (US) (2013 - 2023)

Company Filing History:

18 out of 3,687

Johns Hopkins University

Remd Biotherapeutics, Inc.

5. 1 out of 832,843

Other

patents

where one patent can have more than one assignee

Years Active: 2002-2023

Loading Chart...

36 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11697845 - Directing treatments for glioblastoma based on identifying a somatic structural rearrangement upstream from TERT gene (2023-07-11),

2. 11447555 - Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies (2022-09-20),

3. 11446376 - Methods for treating heart failure using glucagon receptor antagonistic antibodies (2022-09-20),

4. 11332531 - Immunotherapy using antibodies that bind programmed death ligand-1 (PD-L1) (2022-05-17),

5. 11319372 - Cancer treatment using antibodies that bind cytotoxic T-lymphocyte antigen-4 (CTLA-4) (2022-05-03),

6. 11306364 - promoter mutations in gliomas and a subset of tumors (2022-04-19),

7. 11254988 - Somatic mutations in ATRX in brain cancer (2022-02-22),

8. 11248049 - Immunotherapy using antibodies that bind Programmed Death 1 (PD-1) (2022-02-15),

9. 11242398 - Anti-OX40 antibodies and methods of activating OX40 (2022-02-08),

10. 10894987 - Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma (2021-01-19),

11. 10837064 - Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma (2020-11-17),

12. 10765737 - Methods for treating heart failure using glucagon receptor antagonistic antibodies (2020-09-08),

13. 10752693 - Methods for treating obesity and nonalcoholic fatty liver disease or nonalcoholic steatohepatitis using glucagon receptor antagonistic antibodies (2020-08-25),

14. 10711310 - Tert promoter mutations in gliomas and a subset of tumors (2020-07-14),

15. 10704108 - Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma (2020-07-07),

Title: The Innovative Contributions of Hai Yan in Glioblastoma Research

Introduction

Hai Yan, based in Chapel Hill, NC, has distinguished himself as a leading innovator in the field of cancer research, particularly focusing on glioblastoma. With an impressive portfolio of 24 patents, Yan's work has provided significant insights into the molecular underpinnings of various tumors, offering hope for improved treatment strategies.

Latest Patents

Among his most recent patents, Yan has developed methodologies directed at treating glioblastoma by identifying somatic structural rearrangements upstream from the TERT gene. His research highlights that while the majority of glioblastomas can be classified into distinct molecular subgroups based on specific genetic mutations, around 20% lack alterations in both the TERT promoter and IDH genes. These tumors, categorized as TERTp-IDH glioblastomas, have introduced challenges due to a lack of established biomarkers and mechanisms for telomere maintenance. Yan’s work in identifying chromosomal rearrangements in these tumors delineates a novel subgroup that showcases the intricate relationship between telomere maintenance and tumorigenesis.

Career Highlights

Throughout his career, Yan has made substantial contributions to understanding the genetic landscape of glioblastomas and other tumors. His investigations of 1,230 tumors from 60 different types revealed critical distinctions between tumors with low and high frequencies of TERT promoter mutations. This research not only advances our comprehension of cancer biology but also aids in early detection and classification of various tumors.

Collaborations

Yan has collaborated with prominent figures in cancer research, such as Bert Vogelstein and Kenneth W. Kinzler, further fortifying his contributions to the field. His association with esteemed institutions like Johns Hopkins University and Duke University underscores his commitment to groundbreaking research and innovation in oncology.

Conclusion

Hai Yan's innovative work has opened new avenues for understanding and treating glioblastomas, particularly through the identification of unique genetic mechanisms. His patents reflect a deep commitment to advancing cancer research, offering potential pathways for improved diagnostic and treatment options in the fight against cancer. With every advancement, Yan continues to inspire the next generation of researchers and inventors in his field.

This text is generated by artificial intelligence and may not be accurate.